R. Sanchez

A review on toxicities of T-cell engager-based therapies in solid tumors

Etienne Bastien, Clara Vacheret, R. Sanchez, Francesca Lucibello et autres

T-cell engager (TCE)-based therapies represent an emerging and rapidly expanding class of immunotherapies in oncology. Initially developed for hematologic malignancies, TCEs are now entering the field of solid tumors. To date, two agents have received regulatory approval in this setting: Tebentafusp for …

fr (code pays fourni par la source)

MRI-derived tumor burden and growth rate as translational biomarkers: Head-to-head comparison with RECIST and ctDNA in tebentafusp-treated metastatic uveal melanoma.

Toulsie Ramtohul, Xavier-Louis Jasawant, José Luis Sandoval, Léah Mailly-Giacchetti et autres

e21584 Background: Tebentafusp improves survival in metastatic uveal melanoma (mUM), yet RECIST v1.1 responses are uncommon and may not reflect clinical benefit. We evaluated whether early, on-treatment liver MRI volumetric and kinetic biomarkers better predict overall survival (OS) than baseline imaging, ctDNA …

fr (code pays fourni par la source)

Total tumor volume and growth rate at 3 months on MRI outperform baseline imaging and circulating tumor DNA for predicting survival of patients with metastatic uveal melanoma receiving tebentafusp

Toulsie Ramtohul, Xavier-Louis Jasawant, José Luis Sandoval, Léah Mailly-Giacchetti et autres

fr (code pays fourni par la source)

1656P Clinical and molecular outcomes of tebentafusp in metastatic uveal melanoma (MUM): A retrospective cohort of 168 patients

R. Sanchez, T. Ramtohul, Vincent Servois, Gaëlle Pierron et autres

fr (code pays fourni par la source)

LBA58 PLUME: A single-arm phase II trial of pembrolizumab (pembro) plus lenvatinib (lenva) in patients (pts) with metastatic uveal melanoma (mUM)

Manuel Rodrigues, Vincent Servois, R. Sanchez, Estelle Bastien et autres

fr (code pays fourni par la source)

Clinical landscape for patients with head and neck cancers enrolled in phase I trials at a tertiary referral center

Daria Maria Filippini, R. Sanchez, Etienne Bastien, Nicolas Jacquin et autres

Background: Recent advances in understanding the biology of cancer have resulted in an extensive armamentarium of new therapeutic agents, most often tested on various tumor types at the earliest stages of drug development. However, the clinical impact of these therapies on patients …

it, fr (code pays fourni par la source)

The impact of targeted therapies on molecular alterations identified by an institutional molecular tumor board: an approach based on ESCAT classification

Kimya Rahmani Narj Abadi, Célia Dupain, Isabelle Guillou, R. Sanchez et autres

Background The European Society of Medical Oncology Scale for Clinical Actionability of Molecular Targets (ESCAT) classification system provides a standardized framework for categorizing genomic alterations (GAs) of patients with recurrent, metastatic, or rare cancer. This study aimed to present outcomes of patients …

fr (code pays fourni par la source)

Phase I trials of single-agent new drugs in head and neck cancer: a scoping review

Daria Maria Filippini, Grégoire Marret, Etienne Bastien, R. Sanchez et autres

BACKGROUND: The conventional method of drug development in oncology typically progresses through phase I, phase II and randomized phase III trials. Nevertheless, some recent drug approvals for head and neck cancer (HNC) relied on findings from single-arm phase II trials. This underscores …

it, fr (code pays fourni par la source)

319TiP NeoBREASTIM: A phase II study of atezolizumab plus RP1 oncolytic immunotherapy in the neoadjuvant setting of triple-negative breast cancer (TNBC)

Estelle Bastien, Beatriz Grandal, R. Sanchez, T. Ramtohul et autres

fr (code pays fourni par la source)

Abstract B046: A first-in-human Phase 1a/b of PEP-010, a proapoptotic bifunctional peptide, administered as single agent and in combination with paclitaxel in patients with recurrent and/or metastatic solid cancer: results from the dose escalation study

Pauline du Rusquec, Elodie Coquan, Frédérique Berger, Keyvan Rezaï et autres

Abstract Background: PEP-010 is a first-in-class bifunctional peptide that penetrates cells and specifically disrupts the interaction between Caspase9 and PP2A, two proteins involved in the apoptotic cascade, leading to Caspase9-dependent apoptosis in cancer cells. Safety, PK, and preliminary anti-tumor activity from the …

fr (code pays fourni par la source)

Abstract B005: Impact of molecular profiling and ESCAT classification on patient outcome: The experience of Institut Curie Molecular Tumor Board

Maud Kamal, Kimya Rahmani Narj Abadi, R. Sanchez, Célia Dupain et autres

Abstract Introduction: The European Society of Medical Oncology Scale of Actionability of molecular Targets (ESCAT) classification system provides a standardized framework for categorizing genomic alterations (GA) of advanced cancer patients. We aimed to analyze the impact of matched therapies administered based on …

fr (code pays fourni par la source)

PLUME: A single-arm phase II trial evaluating the combination of pembrolizumab and lenvatinib in metastatic uveal melanoma (mUM) patients (pts) previously treated or not with tebentafusp.

Manuel Rodrigues, Mathilde Saint‐Ghislain, Toulsie Ramtohul, Leanne de Koning et autres

TPS9613 Background: Up to 50% of pts with uveal melanoma (UM) develop metastases, mainly hepatic, with poor overall survival and limited treatment options as response rate to first-line immune checkpoint inhibitors (ICI) is low in mUM pts. Tebentafusp, a bispecific T-cell engager, …

fr (code pays fourni par la source)